Ibogaine

Atypical

Ibogaine is a long-acting psychoactive alkaloid from the West African iboga shrub, used traditionally in the Bwiti tradition of Gabon and studied in the West to interrupt opioid and other addictions. It produces a dream-like visionary state lasting more than a day — and carries a serious, potentially fatal risk of heart-rhythm disturbances.

Also known as: Iboga, Tabernanthe iboga, Noribogaine (active metabolite), Eboka, Bwiti sacrament

Written by Psymerge Editorial Team · Last updated June 4, 2026

Key facts

CategoryAtypical
Onset30–90 minutes
Peak4–8 hours (acute visionary phase)
Total duration24–36 hours, with residual effects for days
After-effectsFatigue, insomnia, and impaired coordination for several days

Overview

Ibogaine is an indole alkaloid found in the root bark of the Central and West African shrub Tabernanthe iboga. In Gabon it is central to the Bwiti spiritual tradition, where iboga is taken in initiation ceremonies. In Western settings, ibogaine has drawn attention for a different reason: observational studies suggest a single treatment can sharply reduce opioid withdrawal and craving (Noller et al., 2018; Brown & Alper, 2018).

Pharmacologically it is unusual — an 'atypical' psychedelic or oneirogen that acts on many different receptor systems and produces a long, dream-like, introspective state lasting well over a day, often including a vivid 'life review'. Its main effects are mediated partly through a long-lived active metabolite, noribogaine.

Critically, ibogaine carries a serious cardiac risk: it can prolong the QT interval of the heart's rhythm and trigger potentially fatal arrhythmias, and deaths have been documented (Koenig & Hilber, 2015). For this reason it should only ever be considered under thorough medical screening and continuous monitoring. This page summarises its pharmacology, effects, and substantial risks.

History & origins

Ibogaine is the principal alkaloid of iboga, a plant used for centuries by peoples of Central and West Africa, most famously within the Bwiti tradition of Gabon, where it is taken in large doses during initiation rites and in smaller amounts as a stimulant and aid to concentration. French explorers documented its use in the nineteenth century, and ibogaine was isolated in 1901; in the mid-twentieth century it was even sold in France as a stimulant tonic.

Its anti-addictive properties were popularised from the 1960s onward, notably by Howard Lotsof, who reported that ibogaine interrupted his own opioid dependence. Since then it has been used in a network of clinics and underground settings worldwide to treat addiction, and modern observational studies have documented reductions in opioid withdrawal and use (Noller et al., 2018; Brown & Alper, 2018), even as concern about its cardiac safety has grown.

Pharmacology & how it works

Ibogaine is an indole alkaloid with a complex, multi-target pharmacology: it interacts with NMDA glutamate receptors, kappa- and mu-opioid receptors, sigma receptors, nicotinic acetylcholine receptors, and serotonin transporters. Its long-lived active metabolite, noribogaine, contributes to its prolonged effects. Crucially, both ibogaine and noribogaine block hERG potassium channels in the heart, which prolongs the QT interval and underlies the drug's cardiac risk (Koenig & Hilber, 2015).

Chemical class
Indole alkaloid (atypical psychedelic / oneirogen)
Routes of administration
Oral (root bark, total alkaloid extract, or purified ibogaine HCl)
Tolerance
Ibogaine is not associated with physical dependence; it is studied as a treatment to interrupt addiction rather than a drug of dependence.

Pharmacokinetics

Taken orally, ibogaine comes on over 30–90 minutes and produces a visionary phase of several hours within an overall experience lasting well over a day. It is metabolised to noribogaine, which has a long half-life — this is why QT prolongation and cardiac risk can persist for days after a single dose.

Effects

Physical Effects

  • Pronounced loss of coordination (ataxia); people generally must lie still
  • Nausea and vomiting
  • Changes in heart rate and heart rhythm
  • Heightened sensitivity to light and sound
  • Tremor and difficulty moving for an extended period

Psychological Effects

  • A dream-like, waking visionary state (described as 'oneirogenic')
  • Vivid life-review imagery and autobiographical memories
  • Deep introspection and processing of past experiences
  • Marked reduction in drug craving and withdrawal in addiction treatment
  • Anxiety or distressing material during the long experience

Spiritual Effects

  • Visionary, initiatory experiences central to the Bwiti tradition
  • Encounters with ancestors or inner teachers
  • A sense of profound psychological reckoning or rebirth

Dosage Information

Low: ~1–4 (lower 'psychospiritual' range) mg/kg ibogaine HCl (oral, weight-based)
Medium: ~5–10 mg/kg ibogaine HCl (oral, weight-based)
High: ~10–20 ('flood' dose used for addiction interruption) mg/kg ibogaine HCl (oral, weight-based)

Therapeutic doses are large and calculated by body weight, and root-bark or extract potency varies widely. Because of the cardiac risk, ibogaine should never be dosed without prior medical screening (including an ECG and bloodwork) and continuous monitoring. Educational only and not an endorsement of use.

Risks & safety

Contraindications

Ibogaine has serious cardiac risks, so its contraindications are strict. It should be avoided by:

  • Anyone with a heart condition: heart disease, arrhythmia, a long QT interval, or a family history of sudden cardiac death.
  • People with electrolyte imbalances (such as low potassium or magnesium), which increase arrhythmia risk.
  • People with liver or kidney impairment.
  • People taking QT-prolonging drugs or opioids (see interactions below).
  • People with a personal or family history of psychosis or bipolar disorder.
  • Pregnant or breastfeeding people.

Drug interactions

Ibogaine has dangerous interactions, several of which are potentially fatal.

  • QT-prolonging medications: many drugs (including methadone, certain antibiotics, antipsychotics, and antidepressants) add to ibogaine's effect on heart rhythm and sharply increase arrhythmia risk.
  • Opioids: interactions and the timing of withdrawal are complex and dangerous, and combined use around treatment can be lethal.
  • Stimulants (e.g., cocaine, amphetamines): add cardiovascular strain.
  • Other serotonergic drugs: may raise the risk of serotonin toxicity.

This list is not exhaustive. A clinician must review every medication before any ibogaine use.

Psychological distress & bad trips

The ibogaine experience is exceptionally long and can surface intense, confronting autobiographical and emotional material over many hours, sometimes followed by days of insomnia and emotional rawness. Without skilled support and proper preparation, this can be destabilising, and people with underlying psychiatric vulnerability are at particular risk.

Rare but serious risks

Ibogaine is among the more physically dangerous substances covered here, primarily because of its effects on the heart:

  • Cardiac arrhythmia and sudden death: ibogaine and its metabolite noribogaine block hERG potassium channels, prolonging the QT interval and creating a risk of life-threatening arrhythmias such as Torsade de pointes. This is the leading cause of ibogaine-associated deaths, and the risk can persist for days after a single dose (Koenig & Hilber, 2015). Deaths have occurred even in treatment settings (Noller et al., 2018).
  • Severe ataxia: profound loss of coordination creates a risk of falls and injury.
  • Dangerous drug interactions, especially with opioids and other QT-prolonging medications.
  • Seizures and complications in people with pre-existing heart, liver, or kidney disease.

Vulnerable populations

Many groups face serious, potentially fatal risk and must avoid ibogaine:

  • Anyone with heart disease, arrhythmia, long QT, or a family history of sudden cardiac death.
  • People with electrolyte abnormalities or liver or kidney disease.
  • People taking opioids, methadone, or other QT-prolonging or serotonergic medications.
  • People with a personal or family history of psychosis or bipolar disorder.
  • Adolescents and pregnant or breastfeeding people.

Dependency & addiction potential

Ibogaine itself is not considered addictive; on the contrary, it is studied specifically as a treatment to interrupt dependence on opioids and other drugs (Noller et al., 2018; Brown & Alper, 2018). Its dangers are acute and physical — above all cardiac — rather than related to dependence.

Overdose

The main life-threatening mechanism with ibogaine is cardiac: arrhythmia from QT prolongation rather than classic overdose, and this risk persists for days because of the long-lived metabolite noribogaine. Ibogaine should never be taken without prior medical screening (including an ECG and bloodwork) and continuous cardiac monitoring with resuscitation capability on hand. If someone faints, has palpitations or chest pain, has a seizure, or collapses, seek emergency medical help immediately.

Harm Reduction

  • Never take ibogaine outside a medically supervised setting with pre-screening (ECG, cardiac and liver assessment, electrolytes) and continuous heart monitoring — cardiac arrhythmia is the leading cause of ibogaine deaths.
  • Do not use if you have any heart condition, long QT, arrhythmia, or family history of sudden cardiac death.
  • Disclose all medications: many, including methadone and other QT-prolonging drugs, are dangerous with ibogaine.
  • Never combine with opioids or stimulants around the time of treatment.
  • Ensure trained medical staff and resuscitation equipment are present throughout.
  • Allow several days of supervised recovery, since effects and cardiac risk persist after the acute experience.
  • Use ibogaine for addiction only within a comprehensive program that includes proper aftercare and integration.

Cultural & spiritual context

Iboga is sacred within the Bwiti tradition of Gabon and neighbouring regions, where it is regarded as a profound teacher and is central to initiation, healing, and ancestral connection. These are living traditions with specific ceremonial structures and meanings, and the plant is treated with great seriousness.

In the West, ibogaine occupies an unusual position: it is largely unregulated or prohibited, yet a global network of clinics offers it for addiction treatment, with widely varying standards of medical safety. This raises serious concerns — the real cardiac dangers when screening and monitoring are inadequate, pressure on iboga plant populations and Gabonese traditions from international demand, and questions of cultural respect and sustainability.

Legal Status

Laws vary widely by country and change frequently, so we don't track legal status here to avoid showing outdated information.

Check current worldwide legal status on Psychedelic Alpha

Frequently asked questions

What is ibogaine used for?

Traditionally, iboga is used in the Bwiti spiritual tradition of Gabon for initiation and healing. In the West, ibogaine is best known for its use in interrupting addiction — observational studies report reduced opioid withdrawal and craving after a single treatment (Noller et al., 2018; Brown & Alper, 2018) — though it remains unlicensed and is used in largely unregulated settings.

Why is ibogaine considered dangerous?

Ibogaine can prolong the QT interval of the heart's electrical cycle and trigger life-threatening arrhythmias, and this risk can last for days because of its long-lived metabolite noribogaine (Koenig & Hilber, 2015). Cardiac arrhythmia is the leading cause of ibogaine-associated deaths, which is why medical screening and continuous monitoring are essential.

How long does ibogaine last?

The full experience is unusually long: effects begin within 30–90 minutes, the intense visionary phase lasts several hours, and the overall experience extends to 24–36 hours, with fatigue, insomnia, and impaired coordination often persisting for several days.

Is ibogaine legal?

It varies widely. Ibogaine is a controlled (Schedule I) substance in the United States and prohibited in many countries, legal and regulated in a few (such as New Zealand), and offered in unregulated clinics in others (such as Mexico). Legal status does not guarantee safety.

Is ibogaine addictive?

No. Ibogaine is not itself addictive and is studied specifically as a treatment to interrupt dependence on opioids and other drugs. Its dangers are acute and physical — above all cardiac — rather than related to addiction.

Need Integration Support?

Connect with qualified integration guides who can help you process and integrate your experiences safely and effectively.

Find a Guide

Related substances

2C-B

Psychedelic

2C-B is a synthetic psychedelic phenethylamine first made by Alexander Shulgin and structurally related to mescaline. It is strongly dose-dependent: lower doses feel warm, sensual, and entactogen-like (similar to MDMA), while higher doses are clearly psychedelic, with effects lasting about 4–8 hours.

3-MMC

Synthetic

3-MMC (3-methylmethcathinone) is a synthetic cathinone and 'research chemical' closely related to mephedrone. It is a short-acting stimulant with mild entactogenic effects, a strong tendency to drive compulsive redosing, and significant risks including cardiovascular toxicity and dependence.

4-AcO-DMT

Psychedelic

4-AcO-DMT (psilacetin, O-acetylpsilocin) is a synthetic tryptamine that acts as a prodrug for psilocin — the same active compound produced by magic mushrooms. Its effects are widely reported to be very similar to psilocybin.

5-MeO-DMT

Psychedelic

5-MeO-DMT is an extremely potent, fast-acting psychedelic tryptamine found in the venom of the Sonoran Desert toad and in some plants, and also made synthetically. Rather than the rich visuals of DMT, it tends to produce a sudden, overwhelming experience of ego dissolution and oneness lasting only minutes.

References & further reading

  • Koenig, X., & Hilber, K. (2015). The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules, 20(2), 2208–2228. https://doi.org/10.3390/molecules20022208
  • Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37–46. https://doi.org/10.1080/00952990.2017.1310218
  • Brown, T. K., & Alper, K. (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24–36. https://doi.org/10.1080/00952990.2017.1320802
  • National Institute on Drug Abuse (NIDA). Psychedelic and Dissociative Drugs. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs
  • Global Ibogaine Therapy Alliance (GITA). Clinical Guidelines for Ibogaine-Assisted Detoxification. https://www.ibogainealliance.org/guidelines/
  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug profiles. https://www.emcdda.europa.eu/publications/drug-profiles_en
  • Erowid. Ibogaine Vault. https://www.erowid.org/chemicals/ibogaine/
  • TripSit. Drug combinations chart. https://wiki.tripsit.me/wiki/Drug_combinations

About this article

Written by:
PE
Psymerge Editorial Team
Last updated June 4, 2026